First CiPA Paper is published in Nature Scientific Reports

We are happy to see results from the first large CIPA study that has been published in Nature Scientific Reports. The study was co-authored by Sophions own Anders Lindqvist, but lots of credit should also go to the rest of the team.

  • Kramer et Al. (2020) “Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells”, Nature Scientific Reports volume 10, Article number: 5627

Results from this large multi-site study provide estimates of the variability associated with IC50 values characterizing the blocking potency of 12 drugs on 4 prominent human cardiac currents using suggested experimental protocols across five automated patch platforms and 17 sites.

QPatch results were provided by ourselves and three independent QPatch users (4 in all) and while platforms are anonymized in the paper we can still say that results confirmed what we already knew.

For the record QPatch data was only run at room temperature. With the newly launched temperature control module for QPatch II that enables accurate control of temperature within a range from 10-42°C with a precision of ±0.5°C, we look forward to running more cardiac assays at elevated temperatures. Read more about the QPatch II temperature control solution here.

Also, the original instructions from the Food and Drug Administration (FDA) did not recommend the use of fluoride in the solutions. For most assays on Sophion ‘Qube 384’ we use fluoride to increase the seal resistance, and since it was not recommended, Qube was omitted from this study. We have now learned that others have used fluoride/seal enhancers during this study and agreed with FDA to include Qube in future CiPA studies. We look forward to that since many laboratories already are using Qube for cardiac liability testing.

For questions please contact Sr. Application Scientist Anders Lindqvist